Industry Reports
NxStage® to Report Fourth Quarter and Full Year 2011 Financial Results
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2011 on Wednesday, February 29, 2012 before the...
Industry Reports
Cubist Pharmaceuticals Reports 2011 Fourth Quarter and Full Year Financial Results
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the fourth quarter and year ended December 31, 2011. The Company will host a conference call and webcast today at 5:00 p.m. ET to discuss these results and other...
Industry Reports
Stable consolidated revenues, costs and losses for Hybrigenics
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases and specialised in protein interactions, today presents its consolidated accounts for the first half...
Industry Reports
Hikma Pharma Q1 revenue rises
Hikma Pharmaceuticals, a manufacturer of a range of both branded and non-branded generic and inlicensed products, reported revenue of $394.76m for the first quarter ended 30 June 2011, compared to $357.69m for the same period in 2010. ...
Industry Reports
Furiex Pharmaceuticals Enters into Loan Agreement for up to $15 Million Furiex Pharmaceuticals Inc.
Furiex Pharmaceuticals, Inc. announced it has entered into a loan agreement with MidCap Financial and Silicon Valley Bank to provide up to $15.0 million in capital through a secured term loan. Furiex intends to use the proceeds to support...
Industry Reports
China Shenghuo Q2 sales climb 58%
China Shenghuo, engaged in the research, development, manufacture and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products, has reported sales of $10.9m for the second quarter ended 30 June 2011, an increase of 58% compared to...
Industry Reports
Vivus reports Qnexa phase 3 study results
Vivus, a developer of therapies to address obesity, sleep apnea, diabetes and male sexual health, has reported the data of Qnexa in its Phase 3 study.Qnexa is an once-a-day, oral, controlled-release investigational drug candidate designed to decrease appetite, increase...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read